Multiple Sclerosis Clinical Trials

Showing 5721-5740 of 5,960 trials

Exisulind Versus Placebo After Surgical Removal of the Prostate

NCT00166426

This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.

Prostatic Neoplasms

Mayo Clinic240 participantsStarted Feb 2003

Rochester, Minnesota, United States

COMPLETEDPhase 2

BEYOND Pilot Study

NCT00893217

The purpose of this study is to valuate safety and tolerability of Betaseron.

Multiple SclerosisRelapsing-Remitting

Bayer71 participantsStarted Nov 2002

Los Angeles, California, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +11 more locations

COMPLETEDPhase 1

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00402545

The purpose of this research study is to determine the safest and most effective dose of 5-FU that can be given with docetaxel (Taxotere), Cisplatin and cetuximab to patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. We will also be studying the toxicity of this regimen of 4 drugs and the tumor response.

Head and Neck Neoplasms

Dana-Farber Cancer Institute29 participantsStarted Jan 2007

Boston, Massachusetts, United States

Exisulind Versus Placebo After Surgical Removal of the Prostate

BEYOND Pilot Study

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Related Searches

Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties

Therapeutic Massage to Manage Withdrawal Related Anxiety

High Dose Somatostatin Analogues in Neuroendocrine Tumors

Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer

Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma

Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment

Far Infrared Radiation Treatment for Prostate Cancer

Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

Normal Prostate: Oxygenation of the Prostate Gland in Men Undergoing Prostate Biopsy

A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies

Phase II High-Dose Cyclophosphamide for Multiple Sclerosis

A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.

The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma

Treatment Routes for Exploring Agitation